Peptides for Menopause and Perimenopause: What the Evidence Shows

Key Takeaways

• Compounds covered: Kisspeptin, sermorelin, ipamorelin/CJC-1295, BPC-157, GHK-Cu, collagen peptides, PT-141
• Goal area: Menopause and perimenopause: HPG axis support, bone and muscle preservation, joint health, skin health, sexual health
• Evidence range: Ranges from Phase 3 RCT (PT-141 for HSDD in premenopausal women) to animal-only data (BPC-157 for musculoskeletal applications) to academic clinical research (kisspeptin HPG axis protocols)
• Regulatory range: FDA-approved compound (PT-141/Vyleesi for HSDD in premenopausal women), compounded peptides (sermorelin), contested-compounding peptides (ipamorelin, CJC-1295, kisspeptin), a compound not available through US compounding under Section 503A (BPC-157), cosmetic ingredient (topical GHK-Cu), and dietary supplement (collagen peptides)
• Key biomarkers for menopause: Estradiol, FSH, LH, IGF-1, SHBG, progesterone, hs-CRP, comprehensive metabolic panel
• As of April 2026: No peptide is FDA-approved for menopause symptom management. PT-141 is FDA-approved for HSDD specifically in premenopausal women. The FDA's February 2026 action removed BPC-157 from Category 2 effective April 22, 2026; BPC-157 is not on Category 1 and has no USP/NF monograph, so none of the 503A bulks-pathway eligibility criteria under 21 U.S.C. § 353a(b)(1)(A)(i) is satisfied (PCAC review pending).
• Bottom line: Menopause involves parallel declines in estrogen and growth hormone; different peptides address different components of this biology with very different evidence levels.

Understanding Menopause: The Biology

Menopause is defined clinically as 12 consecutive months without a menstrual period, typically occurring between ages 45 and 55. The underlying biology involves a progressive and eventually near-complete cessation of ovarian estrogen and progesterone production as follicular reserve depletes. This withdrawal from HPG axis feedback drives compensatory increases in LH and FSH from the pituitary.

The neuroendocrinology of this transition is more complex than a simple estrogen withdrawal. Xu and colleagues, in a 2026 review in Comprehensive Physiology, described kisspeptin neurons in the arcuate nucleus as an integrative hub connecting the hypothalamic-pituitary-ovarian axis (HPO), the thyroid axis (HPT), and the stress axis (HPA) during perimenopause — explaining why menopausal transitions involve not just reproductive changes but thyroid function alterations, cortisol dynamics, and metabolic shifts simultaneously. The hot flashes characteristic of perimenopause are hypothesized to arise partly from kisspeptin-mediated hypothalamic activity in the absence of estrogen's inhibitory feedback, though no RCT of kisspeptin for vasomotor symptom management has been published.

Simultaneously and independently, somatopause progresses during the same years. Di Somma and colleagues, in a 2011 review in Minerva Endocrinologica, reviewed the somatopause literature, summarizing the metabolic and body-composition consequences of declining GH secretion. When somatopause and estrogen decline converge in a perimenopausal woman, their respective effects on bone and muscle compound: estrogen loss drives osteosarcopenia directly, and GH decline simultaneously reduces the anabolic signaling that supports bone and lean mass maintenance.

Peptides targeting these processes do not address the same pathways. Compounds relevant to kisspeptin/HPG axis neuroendocrinology, the GH axis, joint tissue repair, and skin collagen each require evaluation on their own mechanistic terms.

Peptides Studied for Menopause and Perimenopause: A Quick Comparison

The following peptides have published evidence relevant to the biological changes of menopause and perimenopause. They are listed by strength of clinical evidence, from most-studied to least.

No compound listed below is FDA-approved for menopause. Inclusion in this list reflects published mechanistic or clinical research relevant to menopausal biology, not a clinical recommendation for any specific application. Regulatory statuses noted below reflect FDA policy as of April 2026; peptide compounding policy is evolving, and current status should be verified with a prescribing provider.

• Compound: PT-141 (bremelanotide / Vyleesi)
  Proposed mechanism and menopausal relevance: Melanocortin receptor agonist acting centrally on sexual motivation circuits; FDA approval covers premenopausal HSDD
  Evidence: Phase 3 RCT (combined RECONNECT 301 and 302 trials, N≈1,247, premenopausal women with HSDD)
  FDA status: FDA-approved for HSDD in premenopausal women; off-label for postmenopausal women
  SP availability: Available through Superpower's licensed provider network for FDA-approved use in premenopausal HSDD only
  Route: Subcutaneous autoinjector (on-demand)
• Compound: Sermorelin (GHRH analog)
  Proposed mechanism and menopausal relevance: GHRH analog stimulating pulsatile GH release; acts on the GH/IGF-1 axis, which contributes to lean mass and bone density maintenance in aging adults with GH decline
  Evidence: Multiple Phase 2 and review-level studies in aging adults with GH decline; no Phase 3 RCT in menopausal women
  FDA status: Not FDA-approved for menopausal applications. Sermorelin has a USP monograph and is eligible for 503A compounding under 21 U.S.C. § 353a(b)(1)(A)(i)(I); available by prescription through licensed compounding pharmacies
  SP availability: Available through Superpower's licensed provider network by prescription; not specifically for menopausal indications
  Route: Subcutaneous injection
• Compound: Ipamorelin / CJC-1295 (GH secretagogues)
  Proposed mechanism and menopausal relevance: GHRP and long-acting GHRH analog proposed to stimulate pulsatile GH release; act on the GH/IGF-1 axis in aging adults with GH decline
  Evidence: Phase 2 and review-level studies in aging and hypogonadal adults; no Phase 3 RCT in menopausal women
  FDA status: Not FDA-approved for any indication. Neither ipamorelin nor CJC-1295 has a USP/NF monograph, and the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted against their inclusion on the 503A Category 1 bulk drug substances list. Their eligibility for legal 503A compounding is contested as of April 2026, and FDA has taken enforcement action against compounding pharmacies producing them
  SP availability: Not currently dispensed by Superpower
  Route: Subcutaneous injection
• Compound: Collagen peptides (oral, low-molecular-weight)
  Proposed mechanism and menopausal relevance: Bioactive dipeptides proposed to stimulate fibroblast collagen synthesis in skin and connective tissue; studied primarily in aging adults, not in specifically menopausal populations
  Evidence: Multiple RCTs in adults; RCT by Lee et al. 2025 in Journal of Microbiology and Biotechnology for skin quality
  FDA status: Dietary supplement; not evaluated for therapeutic claims
  SP availability: Available as a dietary supplement
  Route: Oral
• Compound: GHK-Cu (topical or injectable)
  Proposed mechanism and menopausal relevance: Copper-carrying tripeptide proposed in preclinical models to stimulate collagen synthesis and skin remodeling; no human RCT in menopausal populations
  Evidence: In vitro and preclinical; limited human RCT data for skin outcomes
  FDA status: Topical: cosmetic ingredient. Injectable: not FDA-approved; no USP/NF monograph, not on Category 1 list; eligibility for 503A compounding not established
  SP availability: Topical OTC; injectable not currently available through Superpower
  Route: Topical or subcutaneous injection
• Compound: BPC-157
  Proposed mechanism and menopausal relevance: Cytoprotective pentadecapeptide proposed in preclinical models to accelerate soft tissue healing; no human trial for menopausal musculoskeletal symptoms
  Evidence: Animal studies for musculoskeletal applications; one clinical case series
  FDA status: Not FDA-approved for any medical use. The FDA's February 2026 action removed BPC-157 from Category 2 effective April 22, 2026; not on Category 1 and no USP/NF monograph; no 503A bulks-pathway eligibility criterion satisfied (PCAC review pending)
  SP availability: Not currently available through Superpower
  Route: Subcutaneous injection or oral (research settings only)

Compounds discussed above without an established 503A compounding pathway (ipamorelin, CJC-1295, kisspeptin, injectable GHK-Cu, BPC-157) are not available through Superpower or through licensed US prescribers under any affirmative FDA pathway. Their inclusion in this article is for educational context only. No discussion in this article should be read as a clinical recommendation.

Peptides Studied for Menopause and Perimenopause: Individual Profiles

Each compound below addresses different biology and carries a different evidence base. Profiles are ordered from strongest to weakest clinical evidence.

PT-141 (bremelanotide) for sexual health

PT-141 is a synthetic melanocortin receptor agonist approved as Vyleesi for HSDD in premenopausal women. Sexual health changes are a recognized component of the perimenopausal experience: decreased sexual desire, impaired arousal, and sexual distress affect a significant proportion of women during and after the menopause transition. Parish and colleagues, in the ISSWSH clinical practice guideline published in The Journal of Sexual Medicine in 2021, established the clinical distinction between HSDD in premenopausal women (addressed by PT-141) and postmenopausal low sexual desire, for which testosterone has the stronger evidence base.

The RECONNECT Phase 3 trials, published by Kingsberg and colleagues in Obstetrics and Gynecology in 2019, enrolled premenopausal women with acquired, generalized HSDD and demonstrated statistically significant improvements in sexual desire (FSFI desire domain) and sexual distress (FSDS-DAO item 13) with 1.75 mg bremelanotide on demand. [Phase 3 RCT]

PT-141 is FDA-approved as Vyleesi for premenopausal HSDD. Women in perimenopause who remain premenopausal (defined as fewer than 12 consecutive months without a period) fall within the approved indication. Postmenopausal use is off-label; for that population, the ISSWSH guideline established by Parish and colleagues points toward testosterone therapy rather than bremelanotide as the preferred approach for sexual interest/arousal disorder. Superpower's licensed provider network prescribes PT-141 for its FDA-approved premenopausal HSDD indication only. See the PT-141 compound overview for detailed safety and prescribing information.

GH secretagogues: mechanism and menopausal context

Sermorelin (a GHRH analog), ipamorelin (a selective GHRP), and CJC-1295 (a long-acting GHRH analog) stimulate pulsatile GH release from the pituitary, increasing downstream IGF-1. Their relevance to menopause is rooted in the dual hormonal decline that defines this period: Mandelli and colleagues, writing in Climacteric in 2022, established that estrogen loss drives osteosarcopenia — combined bone and muscle loss — through direct effects on osteoblasts and skeletal muscle, while concurrent somatopause removes GH/IGF-1 anabolic signaling that partially offsets these losses in younger years.

Sinha and colleagues, reviewing GH secretagogues in Translational Andrology and Urology in 2020, documented improvements in lean mass and reductions in fat mass across hypogonadal adult populations receiving GH secretagogue therapy. Rolland and colleagues, in a 2023 review in Metabolism, reviewed GH secretagogues among the investigational medications being evaluated to address sarcopenia, noting that no compound has yet completed Phase 3 trials specifically for this indication. [Multiple Phase 2 / review-level evidence in aging and hypogonadal adults; no Phase 3 RCT in menopausal women]

GH secretagogues are not FDA-approved for menopausal applications. Sermorelin has a USP monograph and is eligible for 503A compounding; it is available through Superpower's licensed provider network by prescription through licensed compounding pharmacies, with prescribing decisions made by the treating provider based on individual clinical context, not specifically for menopausal indications. Ipamorelin and CJC-1295 do not have USP monographs and received a PCAC vote against inclusion on the Category 1 list; their legal compounding status under Section 503A is contested as of April 2026, and they are not currently dispensed by Superpower. Monitoring under any GH axis support protocol requires periodic IGF-1 measurement; elevated IGF-1 outside the reference range is associated with adverse effects. Kościuszko and colleagues, in a 2026 study in International Journal of Molecular Sciences, documented 24-month recombinant human GH (rhGH) intervention effects on vascular biomarkers and body composition in adults with GH deficiency — an adjacent population that provides context for the rationale of extended monitoring during GH-axis therapies, though secretagogue-specific long-term data in menopausal women does not exist.

Kisspeptin: compound discussed but not offered through Superpower

Kisspeptin activates KISS1R receptors on hypothalamic GnRH neurons, and kisspeptin signaling increases as estrogen declines in perimenopause. It is not FDA-approved for any indication, has no USP/NF monograph, has not been placed on the FDA Category 1 bulk drug substances list, and its eligibility for 503A compounding is not established. It is not dispensed by Superpower. The published clinical research is primarily from academic fertility and HPG axis programs at Imperial College London; its relevance to menopause management is an open research question, not an accessible clinical option. [Academic clinical research program; no RCT for menopausal symptom management]

Collagen peptides: skin quality evidence and menopausal relevance

Oral hydrolyzed collagen peptides address the skin-aging component of menopause. Widgerow and colleagues, in a 2026 paper in the Journal of Cosmetic Dermatology, reviewed menopause-associated dermal white adipose tissue depletion as a mechanistic contributor to menopausal skin changes — one component of the broader skin-aging picture that also involves estrogen-driven collagen and elasticity changes. Lee and colleagues published an RCT in the Journal of Microbiology and Biotechnology in 2025 demonstrating that low-molecular-weight collagen peptide supplementation improved skin moisture, elasticity, and wrinkle depth over 8 weeks in healthy adults. [RCT — healthy adults; not specifically menopausal women]

Regulated as a dietary supplement. Available without a prescription. Studied primarily for general skin and connective tissue outcomes in aging adults; not evaluated for vasomotor, musculoskeletal, or hormonal symptom management.

BPC-157: preclinical soft tissue repair research

BPC-157 is not FDA-approved for any medical use. The FDA's February 2026 action removed BPC-157 from the Category 2 bulk drug substances list effective April 22, 2026. BPC-157 has not been placed on the Category 1 list and does not have a USP/NF monograph. None of the three 503A bulks-pathway eligibility criteria under 21 U.S.C. § 353a(b)(1)(A)(i) is satisfied. BPC-157 is therefore not eligible for 503A compounding under any enumerated bulks-pathway path as of April 2026; PCAC review remains pending. It is not available through Superpower or any licensed US prescriber under the current regulatory framework. The research literature on BPC-157, as of April 2026, is limited to animal studies and a single clinical case series.

Strand and colleagues, reviewing pain during menopause in Maturitas in 2025, documented widespread musculoskeletal pain, joint symptoms, and fibromyalgia-like presentations as characteristic features of the perimenopausal and postmenopausal periods. BPC-157 has preclinical evidence for soft tissue repair, and Seiwerth and colleagues, in a 2021 review in Frontiers in Pharmacology, summarized BPC-157's wound-healing and tissue-repair profile across animal studies. However, these animal study findings have not been tested in human trials for any musculoskeletal indication, let alone menopausal joint symptoms specifically. [Animal studies; one clinical case series for knee pain — Lee & Padgett, Altern Ther Health Med 2021]

Regulatory Status at a Glance

As of April 2026, the peptides discussed in this article carry different regulatory statuses.

• PT-141 (bremelanotide / Vyleesi): FDA-approved for HSDD in premenopausal women. Postmenopausal use is off-label. For postmenopausal sexual interest/arousal disorder, testosterone therapy has stronger guideline support.
• Sermorelin: Not FDA-approved for any menopausal indication. Sermorelin has a USP monograph and meets the bulk drug substance eligibility criteria under 21 U.S.C. § 353a(b)(1)(A)(i)(I), making it legally compoundable under Section 503A for appropriate patient-specific prescriptions. Available by prescription through licensed compounding pharmacies.
• Ipamorelin: Not FDA-approved for any indication. Ipamorelin does not have a USP/NF monograph and does not appear on the FDA Category 1 bulk drug substances list; the FDA's Pharmacy Compounding Advisory Committee recommended against its inclusion. Its status as a legally compoundable substance under 503A is contested as of April 2026, and FDA has taken enforcement action against compounding pharmacies producing ipamorelin. Superpower does not currently dispense ipamorelin.
• CJC-1295: Not FDA-approved for any indication. CJC-1295 does not have a USP/NF monograph and does not appear on the FDA Category 1 bulk drug substances list; PCAC recommended against its inclusion. Its status as a legally compoundable substance under 503A is contested as of April 2026, and FDA has taken enforcement action against compounding pharmacies producing CJC-1295. Superpower does not currently dispense CJC-1295.
• Kisspeptin: Not FDA-approved for any indication. Kisspeptin does not have a USP/NF monograph and has not been placed on the FDA Category 1 bulk drug substances list. Its eligibility for 503A compounding is not established, and Superpower does not dispense kisspeptin.
• Collagen peptides (oral): Dietary supplement under DSHEA; not evaluated by FDA for therapeutic claims.
• GHK-Cu (topical): Cosmetic ingredient; regulated as cosmetic, not drug; available OTC.
• GHK-Cu (injectable): Not FDA-approved for any indication. Does not have a USP/NF monograph and is not on the FDA Category 1 bulk drug substances list. Its eligibility for 503A compounding is not established. Not available through Superpower.
• BPC-157: Not FDA-approved for any medical use. The FDA's February 2026 action removed BPC-157 from the Category 2 bulk drug substances list effective April 22, 2026. BPC-157 is not on Category 1 and does not have a USP/NF monograph; no 503A bulks-pathway eligibility criterion under 21 U.S.C. § 353a(b)(1)(A)(i) is satisfied (PCAC review pending). Not available by prescription in the US.

Compounds listed above without an affirmative 503A compounding pathway (ipamorelin, CJC-1295, kisspeptin, injectable GHK-Cu, BPC-157) are not available through Superpower. Their presence in this article is for educational context only.

Considerations When Comparing Peptides for Menopause

Menopause is not one biological event but several concurrent processes, and different peptides address different ones. A clinical evaluation of which process is the priority concern — and whether any peptide is mechanistically appropriate for it — requires provider-level assessment of symptoms, lab values, and health history.

Direct comparison between these compounds is not straightforward. They have been studied in different populations, at different doses, and using different endpoints. Inferring relative effectiveness from separate trials is methodologically unreliable.

Menopausal status and HPG axis position: Whether a woman is perimenopausal (HPG axis still cycling but dysregulated), early postmenopausal (estrogen very low, FSH elevated), or further postmenopausal affects which compounds are even mechanistically relevant. PT-141's FDA approval applies to premenopausal women; GH secretagogues are relevant across both stages; kisspeptin's role shifts as the menopausal transition completes.

Priority symptom: Vasomotor symptoms (hot flashes), joint pain, sexual health, bone density, or skin changes all point toward different compounds and different evidence bases. Identifying the priority concern narrows the clinical discussion efficiently.

Concurrent HRT status: Women on HRT are managing the estrogen axis with an established pharmacological approach. Whether adding a GH secretagogue is appropriate in that context is a provider-level decision requiring assessment of baseline IGF-1, metabolic status, and current medications. No interaction data exists for GH secretagogues combined with common HRT formulations.

Evidence level: PT-141 has Phase 3 trial data for its specific indication. GH secretagogues have Phase 2-level and review evidence in aging adults. BPC-157 has animal data only. These are not equivalent levels of evidence, and your provider will factor evidence quality into any clinical recommendation.

This is not an exhaustive list of clinical considerations. A licensed provider will evaluate your full health history, current medications, and baseline lab results before recommending any compound.

Safety Considerations

Safety profiles across this list vary considerably and cannot be generalized. Several points apply broadly to the menopausal population.

For GH secretagogues specifically: women with hormone-sensitive conditions require oncology-aware provider evaluation before GH axis stimulation. The theoretical interaction between elevated IGF-1 and hormone-sensitive tissue has not been resolved in this population. Women on concurrent HRT should disclose this to the prescribing provider.

PT-141 produces transient blood pressure elevation and is contraindicated in women with cardiovascular disease or uncontrolled hypertension. Perimenopause is a period of increasing cardiovascular risk, and a thorough cardiovascular risk assessment is part of appropriate prescribing.

Kisspeptin's safety profile comes primarily from academic research injection protocols, not commercial compounding contexts. Long-term safety data from commercial use settings does not exist.

Contraindications that apply broadly to menopausal women considering peptide therapy include:

• Hormone-sensitive malignancy (current or history) — requires oncology-aware evaluation for any compound affecting GH/IGF-1 or reproductive hormone axes
• Cardiovascular disease or uncontrolled hypertension — contraindicated for PT-141; relevant for any compound affecting vascular tone
• Active metabolic conditions (uncontrolled diabetes, severe insulin resistance) — GH axis stimulation can affect glucose metabolism
• Current or planned pregnancy — no peptides in this list have established safety in pregnancy

For compound-specific side effect profiles, see the individual compound pages linked above.

What to Test Before Starting Peptides for Menopause

Regardless of which compound a provider discusses, baseline biomarker testing establishes a measurable starting point. Without it, there is no objective way to assess whether a compound is producing the expected physiological changes — or whether those changes are beneficial.

• Estradiol: The primary marker of menopausal status and estrogen decline. Estradiol testing characterizes the HPG axis position and the degree of estrogenic change driving the symptom profile.
• FSH: Elevated FSH on repeat testing is the laboratory hallmark of perimenopause and menopause. FSH pairs with estradiol to stage the transition and confirm primary ovarian insufficiency versus central suppression.
• LH: Upstream pituitary gonadotropin whose pattern — along with FSH — characterizes the pituitary's response to declining ovarian feedback. Testing LH is part of any comprehensive reproductive hormone evaluation.
• IGF-1: The primary tracking marker for GH secretagogue therapy. A baseline IGF-1 establishes GH axis status and is required before and during any GH secretagogue protocol to confirm response and identify levels outside the reference range.
• SHBG: Modulates the bioavailability of estradiol and testosterone. Changes in SHBG during menopause affect free hormone fractions; testing SHBG provides hormone bioavailability context that affects clinical interpretation.
• Progesterone: Relevant in perimenopausal women who are still cycling irregularly; establishes luteal phase function. Testing progesterone helps characterize cycle status and anovulatory frequency in perimenopause.
• hs-CRP: Systemic inflammation is elevated in menopause, and musculoskeletal pain correlates with inflammatory burden. A baseline hs-CRP provides the inflammatory context relevant to any compound proposed for joint or tissue health.
• Comprehensive metabolic panel: Liver and kidney function establish the safety baseline for injectable compounds; glucose and electrolytes provide metabolic context relevant to GH axis compounds.

Estradiol, FSH, LH, IGF-1, and SHBG together characterize both the HPG axis and GH axis — the two hormonal systems most relevant to the biology of menopause. Testing at baseline, 3 months, and 6 months provides a timeline that makes any biological change interpretable against an objective starting point. The hormonal balance and energy biomarker guide covers these markers and their clinical significance in midlife women.

How to Access These Peptides Safely

Every injectable peptide discussed here requires a prescription from a licensed healthcare provider. PT-141 (Vyleesi) is available as the FDA-approved product through licensed prescribers and pharmacies. Among GH secretagogues, sermorelin has a USP monograph and is eligible for 503A compounding; ipamorelin and CJC-1295 received a PCAC vote against 503A Category 1 inclusion and their legal compounding status under Section 503A is contested as of April 2026. Kisspeptin does not have a USP monograph or Category 1 placement; its 503A compounding eligibility is not established, and it is not dispensed by Superpower. BPC-157 was removed from Category 2 by the FDA's February 2026 action effective April 22, 2026; it is not on Category 1 and has no USP/NF monograph, so no 503A bulks-pathway eligibility criterion is satisfied (PCAC review pending). Not dispensed by Superpower.

A provider evaluation for any menopausal peptide application involves: reproductive hormone panel and IGF-1 at minimum; a review of current and prior medical history (including any hormone-sensitive conditions); a medication review (including HRT, if applicable); and a symptom-specific assessment. Self-directed use eliminates the safety monitoring that makes peptide therapy interpretable and clinically appropriate.

Oral collagen peptides and topical GHK-Cu are available without a prescription and are regulated as dietary supplement and cosmetic ingredient categories respectively.

Understanding Your Baseline

Menopause involves multiple simultaneous biological changes — in the HPG axis, the GH axis, inflammatory burden, skin biology, and musculoskeletal tissue. No single peptide addresses all of them, and the evidence quality for specific applications varies from Phase 3 RCT (PT-141 for premenopausal HSDD) to animal data only (BPC-157 for joint symptoms). Knowing which changes are measurably present in a specific individual transforms a general question about "peptides for menopause" into a focused clinical question about which mechanism matches what the labs actually show.

That principle — test first, then decide — is central to Superpower's approach to preventive health. Whether the conversation with a provider leads to an FDA-approved compound, a compounded formulation, or a non-pharmacological approach, the starting point is the same: objective biomarker data that reflects where the biology actually stands.

IMPORTANT SAFETY INFORMATION

PT-141 (bremelanotide) is FDA-approved as Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is a prescription medication. Full prescribing information is available in the FDA-approved labeling. Use in postmenopausal women is off-label and not supported by dedicated clinical trials. Contraindications: cardiovascular disease, uncontrolled hypertension, concomitant use of certain antihypertensive medications, known hypersensitivity. Warnings: transient blood pressure increase at peak plasma concentration; hyperpigmentation with repeated use. Common side effects: nausea (~40%), flushing (~20%), injection site reactions, headache. Full prescribing information at dailymed.nlm.nih.gov.

Sermorelin is not FDA-approved for any indication. Sermorelin has a USP monograph and meets the bulk drug substance eligibility criteria under 21 U.S.C. § 353a(b)(1)(A)(i)(I), making it legally compoundable under Section 503A for patient-specific prescriptions at the treating provider's determination. Compounded sermorelin is not an FDA-approved product; compounding is not evaluated by FDA for safety, efficacy, or quality for any specific clinical use. Safety and efficacy of sermorelin for menopausal or women's health indications have not been established through adequate and well-controlled clinical trials. Superpower's licensed provider network may prescribe sermorelin where a treating provider determines it is clinically appropriate for an individual patient based on their clinical presentation; Superpower does not market sermorelin for menopausal indications.

Ipamorelin is not FDA-approved for any indication. Ipamorelin does not have a USP/NF monograph and does not appear on the FDA Category 1 bulk drug substances list; PCAC recommended against its inclusion. Its status as a legally compoundable substance under 503A is contested as of April 2026. Safety and efficacy for menopausal indications have not been established. Superpower does not currently dispense ipamorelin.

CJC-1295 is not FDA-approved for any indication. CJC-1295 does not have a USP/NF monograph and does not appear on the FDA Category 1 bulk drug substances list; PCAC recommended against its inclusion. Its status as a legally compoundable substance under 503A is contested as of April 2026. Safety and efficacy for menopausal indications have not been established. Superpower does not currently dispense CJC-1295.

Kisspeptin is not FDA-approved for any indication. It does not have a USP/NF monograph and has not been placed on the FDA Category 1 bulk drug substances list; its eligibility for 503A compounding is not established. It is not prescribed, compounded, or dispensed through Superpower. Research is primarily from academic fertility and HPG axis studies; safety and efficacy for menopausal symptom management have not been established.

Collagen peptides discussed in this article are dietary supplements. Statements about dietary supplements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.

GHK-Cu topical is a cosmetic ingredient regulated as a cosmetic, not a drug. Cosmetic claims only; not evaluated or approved to diagnose, treat, cure, or prevent any disease.

BPC-157 is not approved by the FDA for any medical use. The FDA's February 2026 action removed BPC-157 from the Category 2 bulk drug substances list effective April 22, 2026. BPC-157 is not on Category 1 and does not have a USP/NF monograph; no 503A bulks-pathway eligibility criterion under 21 U.S.C. § 353a(b)(1)(A)(i) is satisfied (PCAC review pending). Research is primarily from animal studies; safety, efficacy, dosing, and long-term effects in humans have not been established. BPC-157 is not prescribed, compounded, or dispensed through Superpower.

Full FDA-approved prescribing information at dailymed.nlm.nih.gov.